Table 4.

Parameters of the optimized regression model for whole COVID virus-specific CD4+ and CD8+ T-cell response.

Characteristic	exp (Beta)	95% CI1	p-value
Sampling Interval	0.94	0.89, 1.00	0.044
Age	0.98	0.96, 0.99	<0.001
Targeted therapies
anti-CD20	0.35	0.12, 1.01	0.055
IL-6 inhibitor	0.98	0.53, 1.79	>0.9
JAK inhibitor	1.25	0.48, 3.22	0.6
TNF-α inhibitor	0.94	0.63, 1.39	0.7

Both cohorts. This parameter also shows age dependence (2% decrease by each year) (p<0.001). In each month the whole COVID virus-specific CD4+ and CD8+ T-cell response decreases by 6% (p=0.044). In a patient who is treated with anti-CD20 therapy the expected T-cell response is 65% smaller (p=0.055).

¹CI, Confidence Interval.